GS-US-380-1474: Switch to BIC/FTC/TAF Safely Maintains Virologic Suppression at Week 48 in Children and Adolescents With HIV Infection

Expert commentary from Anthony Mills, MD, on his optimistic outlook for patient uptake of long-acting injectable ART.

Anthony M. Mills, MD Released: December 11, 2019

CCO downloadable slides on new HIV data from IDWeek 2019 and EACS 2019: PrEP, first-line and switch options, weight gain with ART, options in pregnancy

Joseph J. Eron, Jr., MD
Program Director Princy N. Kumar, MD, FIDSA, MACP
Program Director David A. Wohl, MD Released: December 5, 2019

Downloadable slideset from CCO on key HIV data presented at the 2019 IDWeek and EACS meetings as selected by Drs. Cristina Mussini and David A. Wohl

Cristina Mussini, MD David A. Wohl, MD Released: December 2, 2019

Slides do CCO e da Dra. Beatriz Grinsztejn sobre o gerenciamento do HIV no Brasil: informações especializadas sobre a escolha da TARV nas configurações de primeira linha, switch e coinfecção por TB

Beatriz Grinsztejn, MD, PhD
Program Director Erico Arruda, MD, PhD Monica Jacques de Moraes, MD, PhD Estevão Portela Nunes, MD, PhD Released: November 22, 2019